View Older Stories View More Recent Stories
-
Penumbra surges on news of $14.5 billion Boston Scientific buyout, BSX down
-
Boston Scientific (BSX) Removed from Citi Focus List
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
UBS on Boston Scientific (BSX): Risk/Reward Into 2026 Skewed to the Upside
-
TD Cowen on Boston Scientific (BSX): 'We See Sustained Momentum Driving Multiple Re-Expansion'
-
Raymond James Publishes 31st Annual Analyst Best Picks List for 2026
-
Nephron Downgrades Boston Scientific (BSX) to Hold
-
These 2 MedTech companies can continue to gain EP share in 2026: BofA
-
This medical technology firm has a "best-in-class portfolio," UBS says
-
Boston Scientific director Sununu will not seek re-election in 2026
-
Canaccord Genuity Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $140 at UBS
-
Boston Scientific (BSX) PT Raised to $130 at Leerink Partners
-
Boston Scientific (BSX) PT Raised to $124 at Goldman Sachs
-
Stifel on Boston Scientific (BSX): 'We expect especially positive growth contributions from Watchman and Electrophysiology'
-
BTIG: 'we think BSX remains a name to own'
-
Boston Scientific (BSX) PT Raised to $113 at Evercore ISI
-
Boston Scientific (BSX) Tops Q3 EPS by 4c; beats on guidance
-
TD Cowen on Boston Scientific (BSX): 'remains our top pick'
-
Evercore Adds Names to TAP Lists
-
Piper Sandler on Boston Scientific (BSX): 'Why Didn't Shares of BSX Respond Better to Its Analyst Day?'
-
Erste Group Downgrades Boston Scientific (BSX) to Hold
-
TD Cowen on Boston Scientific (BSX): 'Today's Portfolio Review Should Reinvigorate the Bull Case'
-
RBC Capital on Boston Scientific (BSX): 'We See the I-Day as a Clearing Event'
-
Stifel Reiterates Buy Rating on Boston Scientific (BSX)
-
Piper Sandler on Boston Scientific (BSX): 'Still Our Favorite LC Diversified'
-
Bernstein Calls Boston Scientific (BSX) a 'Great Stock Story'
-
Oppenheimer Reiterates Outperform Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $129 at Truist Securities
-
Boston Scientific (BSX) PT Raised to $132 at Canaccord Genuity
-
Boston Scientific (BSX) PT Raised to $132 at BTIG
-
RBC Capital on Boston Scientific (BSX): 'Bullish on Next Leg of Growth'
-
Piper Sandler: 'Boston Scientific (BSX) Poised for Success with a Durable Tailwind to Follow'
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Stifel: Electrophysiology Market Growth is Healthy
-
Wolfe sees a buying opportunity in this stock ahead of an important catalyst
-
Needham on Boston Scientific (BSX): 'one of the highest quality large-cap med tech companies'
-
Morgan Stanley unveils 16 ‘Vintage Values’ stocks for 2026
-
Needham Reiterates Buy Rating on Boston Scientific (BSX)
-
Morgan Stanley lists top value stocks to own for 2026
-
Elutia sells BioEnvelope business to Boston Scientific for $88 million
-
Boston Scientific (BSX) PT Raised to $127 at Leerink Partners
-
Oppenheimer Upgrades Boston Scientific (BSX) to Outperform
-
Boston Scientific executive Jeffrey Mirviss to retire in December
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
FDA Aware Of Boston Scientific (BSX) Defibrillation Lead Issue
-
Boston Scientific (BSX) PT Raised at RBC Capital on 'Strong Business Momentum'
-
Boston Scientific (BSX) PT Raised at Truist; 'Strong Qtr w/Multiple Tailwinds'
